Amarin Plunges After Vascepa Patents Are Invalidated
- Dr. Reddy’s, Hikma are seeking to sell copy of fish-oil drug
- Vascepa sales account for almost all of Amarin’s revenue
This article is for subscribers only.
Amarin Corp. plunged in after-hours trading after a U.S. judge invalidated its patents on the heart treatment Vascepa, opening the door to low-cost versions of a drug that accounts for almost all of its revenue.
Amarin pledged to appeal.